notificationsアラート設定
~
検索条件をクリア

アブストラクト

Title オランザピン (ジプレキサ(R)錠)
Subtitle 特集 急な提案・問い合わせにしっかり備える がん患者の支持療法薬
Authors 林稔展
Authors (kana)
Organization 福岡大学薬学部臨床薬学教室
Journal 月刊薬事
Volume 64
Number 9
Page 1757-1762
Year/Month 2022 / 7
Article 報告
Publisher じほう
Abstract [Key Point] ●高度催吐性リスク化学療法に対する従来の標準的3剤併用制吐療法にオランザピンを追加することで, 制吐効果の向上が期待できる. ●制吐薬としてのオランザピンの標準投与量は5mgである. ●副作用として鎮静(眠気)や高血糖などに注意する. ●高齢者(特に75歳以上)の使用経験は乏しいため, 慎重に検討したうえで投与する.
Practice 薬学
Keywords
  • 全文ダウンロード： 従量制、基本料金制の方共に803円(税込) です。
download全文ダウンロード(2.27MB)

参考文献

  • 1) 日本癌治療学会 : 制吐薬適正使用ガイドライン 第2版 ver.2.2. 2018(http://www.jsco-cpg.jp/item/29/index.html)
  • 2) Herrstedt J, et al : 2016 Updated MASCC/ESMO Consensus Recommendations : Prevention of Nausea and Vomiting Following High Emetic Risk Chemotherapy. Support Care Cancer, 25 : 277-288, 2017
    pubmed
  • 3) Hesketh PJ, et al : Antiemetics : ASCO Guideline Update. J Clin Oncol ; 38 : 2782-2797, 2020
    pubmed
  • 4) National Comprehensive Cancer Network : NCCN clinical practice guidelines in oncology ; Antiemetics Version 2. 2022(https://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf)
  • 5) Tamura K, et al ; CINV Study Group of Japan : Testing the effectiveness of antiemetic guidelines : results of a prospective registry by the CINV Study Group of Japan. Int J Clin Oncol, 20 : 855-865, 2015
残りの15件を表示する
  • 6) Navari RM, et al : Olanzapine for the prevention of chemo-therapy-induced nausea and vomiting. N Engl J Med, 375 : 134-142, 2016
  • 7) Yanai T, et al : A double-blind randomized phase II dose-finding study of olanzapine 10 mg or 5 mg for the prophylaxis of emesis induced by highly emetogenic cisplatin-based chemotherapy. Int J Clin Oncol, 23 : 382-388, 2018
  • 8) Hashimoto H, et al : Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting(J-FORCE) : a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol, 21 : 242-249, 2020
  • 9) Nakamura M, et al : A prospective observational study on effect of short-term periodic steroid premedication on bone metabolism in gastrointestinal cancer(ESPRESSO-01). Oncologist, 22 : 592-600, 2017
  • 10) Okada Y, et al : Three-day dexamethasone in combination with palonosetron for the prevention of chemotherapy-induced nausea and vomiting : A systematic review and individual patient data-based meta-analysis. Oncologist, 24 : 1593-1600, 2019
    pubmed
  • 11) Ito Y, et al : Placebo-Controlled, double-blinded phase III study comparing dexamethasone on day 1 with dexamethasone on days 1 to 3 with combined neurokinin-1 receptor antagonist and palonosetron in high-emetogenic chemotherapy. J Clin Oncol, 36 : 1000-1006, 2018
    pubmed
  • 12) Shimomura K, et al : Placebo-controlled, double-blinded phase III study comparing dexamethasone on day 1 with dexamethasone on days 1 to 4, with combined neurokinin-1 receptor antagonist, palonosetron, and olanzapine in patients receiving cisplatin-containing highly emetogenic chemo-therapy ; SPARED trial. Ann Oncol, 32 : S1283-S1346, 2021
  • 13) Iihara H, et al : Efficacy and safety of 5 mg olanzapine combined with aprepitant, granisetron and dexamethasone to prevent carboplatin-induced nausea and vomiting in patients with gynecologic cancer : A multi-institution phase II study. Gynecol Oncol, 156 : 629-635, 2020
  • 14) Tanaka K, et al : Olanzapine-containing antiemetic therapy for the prevention of carboplatin-induced nausea and vomiting. Cancer Chemother Pharmacol, 84 : 147-153, 2019
    pubmed
  • 15) Naik RD, et al : Olanzapine for prevention of vomiting in children and adolescents receiving highly emetogenic chemotherapy : Investigator-initiated, randomized, open-Label trial. J Clin Oncol, 38 : 3785-3793, 2020
  • 16) Navari RM, et al : The use of olanzapine versus metoclopramide for the treatment of breakthrough chemo-therapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Support Care Cancer, 21 : 1655-1663, 2013
  • 17) Maeda A, et al : Effects of 5-mg dose of olanzapine for breakthrough nausea and vomiting in patients receiving carboplatin-based chemotherapy : a prospective trial. Ann Palliat Med, 10 : 2699-2708, 2021
    pubmed
  • 18) 林 稔展, 他 : がん化学療法に対する制吐薬としてのオランザピン使用実態調査. 2018(http://jascc.jp/wp/wp-content/uploads/2019/01/olanzapine_v2.3.pdf)
  • 19) Arai H, et al : J-CATIA Study Group : Mortality risk in current and new antipsychotic Alzheimer's disease users : Large scale Japanese study. Alzheimers Dement, 12 : 823-830, 2016
  • 20) 日本がんサポーティブケア学会 : 制吐薬としてオランザピンを使用する上での注意点. 2017(http://jascc.jp/wp/wp-content/uploads/2017/09/info_20170821_m.pdf)
はじめての方へ
個人／法人会員登録のご案内